Consolidated net sales for the third quarter of fiscal year ending March 2026 were JPY 64,077 million (down 1.1% YoY), operating income was JPY 8,566 million (down 16.4% YoY), and net income attributable to owners of parent for the quarter was JPY 5,554 million (down 32.5% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4559-20260205-01.pdf","jir_short_summary":"Consolidated net sales for the third quarter of fiscal year ending March 2026 were JPY 64,077 million (down 1.1% YoY), operating income was JPY 8,566 million (down 16.4% YoY), and net income attributable to owners of parent for the quarter was JPY 5,554 million (down 32.5% YoY).","jir_summary":"### Overview of Financial Performance\nConsolidated net sales for the third quarter of fiscal year ending March 2026 amounted to JPY 64,077 million, a decrease of 1.1% year-over-year. Operating income decreased to JPY 8,566 million (down 16.4% YoY) due to lower sales, increased costs including raw materials, and higher expenses related to core system investments at overseas subsidiaries. Ordinary income declined to JPY 7,286 million (down 31.7% YoY), affected by foreign exchange losses. Net income attributable to owners of parent for the quarter was JPY 5,554 million, down 32.5% YoY. By segment, the prescription pharmaceutical business recorded net sales of JPY 42,403 million (down 0.6% YoY), while the consumer healthcare business posted JPY 21,560 million (down 1.9% YoY).\n\n### Financial Position and Outlook\nAt the end of the third quarter, total assets stood at JPY 166,225 million, net assets at JPY 96,176 million, and the equity ratio improved to 57.8%, up 1.5% year-over-year. The number of issued shares was 51,119,190, a decrease of 2,000,000 shares from the prior year period, with treasury stock also reduced to 7,039,792 shares. Full-year earnings guidance remains unchanged, projecting net sales of JPY 90,000 million (up 3.1% YoY), operating income of JPY 12,000 million (down 1.6% YoY), and net income attributable to owners of parent of JPY 9,500 million (down 4.4% YoY). Despite exchange rate uncertainty, a recovery in the overseas prescription pharmaceutical business is anticipated.","jir_financial_highlights":"Net Sales: JPY 64,077 million (Down 1.1% YoY)\nOperating Income: JPY 8,566 million (Down 16.4% YoY)\nOrdinary Income: JPY 7,286 million (Down 31.7% YoY)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 5,554 million (Down 32.5% YoY)\nEquity Ratio: 57.8% (Up 1.5% YoY)\nNumber of Issued Shares (Including Treasury Stock): 51,119,190 shares (Down 2,000,000 shares YoY)\nNumber of Treasury Shares at Period End: 7,039,792 shares (Down 2,000,000 shares YoY)\nFull-Year Earnings Guidance Net Sales: JPY 90,000 million (Up 3.1% YoY)\nFull-Year Earnings Guidance Operating Income: JPY 12,000 million (Down 1.6% YoY)\nFull-Year Earnings Guidance Net Income Attributable to Owners of Parent: JPY 9,500 million (Down 4.4% YoY)","jir_category":"","jir_hashtags":"#ZeriaPharmaceuticalCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 64,077 million (Down 1.1% YoY)\nOperating Income: JPY 8,566 million (Down 16.4% YoY)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 5,554 million (Down 32.5% YoY)","jir_meta_title":"Zeria Pharmaceutical Q3 FY2026 Financial Summary: Net Sales JPY 64 Billion, Net Income Down 32.5%","jir_meta_description":"Zeria Pharmaceutical Co., Ltd. announces its Q3 FY2026 financial summary with net sales of JPY 64,077 million (down 1.1% YoY), operating income of JPY 8,566 million (down 16.4%), and net income attributable to owners of parent of JPY 5,554 million (down 32.5%).","jir_og_title":"Zeria Pharmaceutical Announces Q3 FY2026 Financial Results","jir_og_description":"Net sales of JPY 64,077 million, operating income of JPY 8,566 million, and net income of JPY 5,554 million, showing decreases compared to the same period last year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[64773,64077],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[10246,8566],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[8226,5554],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Sales Composition Ratio Q3 FY2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Prescription Pharmaceutical Business\\\",\\\"Consumer Healthcare Business\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"data\\\":[42403,21560,113],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#76b7b2\\\"]}]}}\"}, {\"jir_chart_id\": \"equity_ratio_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trend (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Year-End\\\",\\\"Q3 FY2026 End\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Equity Ratio\\\",\\\"data\\\":[56.3,57.8],\\\"borderColor\\\":\\\"#59a14f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false,\\\"min\\\":50,\\\"max\\\":60}}}}\"}]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24842","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n